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Introduction
Clopidogrel is a thienopyridine that irreversibly inhibits
platelet P2Y12 receptors and adenosine diphosphate (ADP)
mediated platelet aggregation. It is a prodrug that requires
activation in the liver by cytochrome P450 enzymes
(CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, and/or
CYP2B6) 
1.
Dual antiplatelet therapy with clopidogrel and aspirin
has become the mainstay of treatment of patients with acute
coronary syndromes undergoing percutaneous coronary in-
tervention
2–4.
Clopidogrel response
Despite significant benefits of the combined antiplatelet
treatment in large clinical trials, the occurrence of adverse is-
chemic events remains a serious clinical problem 
5–7. Clinical
trials have shown that 8%–10% of patients experience a re-
current cardiovascular event during the first year after acute
coronary syndromes and 1%–3% an acute or subacute stent
thrombosis after percutaneous coronary intervention 
8, 9.
A possible reason for these adverse events might be
the fact that clopidogrel’s antiplatelet effect is not uniform
in all patients. Many studies have shown that individual re-
sponse variability to this thienopyridine derivate and the
prevalence of individuals, who are deemed to have an in-
adequate response to clopidogrel therapy, varies between
4% and 30% 
10–12. Unfortunately, clopidogrel resistance it-
self is not yet clearly understood and there is no apparent
consensus on the definition of clopidogrel resistance. Also,
there are significant differences between the platelet func-
tion tests used, agonist concentrations, and cut-off points.
Nevertheless, the term clopidogrel resistance should gener-
ally be limited to those who fail to achieve a desired phar-
macological response to drug therapy, rather than patients
who experience recurrent ischemic events while on anti-
thrombotic therapy 
13.
Monitoring of clopidogrel action
Until the early 1990’s bleeding time was still consid-
ered as the most useful test for the detection of platelet func-
tion. Recently, many better tests have become available that
may be used to assess the influence of antithrombotic drugs
on platelet. Despite that, methodological variability within
each technique makes it difficult to compare results, and it is
associated with unclear role of platelet function testing in
clinical practice.
In this paper we discuss about the most used tests in
practice which examine platelet function and agreggation,
which is indirect way to evaluate response to clopidogrel.
Light transmission aggregometry (LTA) has been re-
garded as the gold standard for assessing platelet function for
more than two decades. Aggregation of platelets is tradition-
ally measured in platelet rich plasma (PRP) using an optical
aggregometer. Aggregation response is simulated by adding
of an agonist (ADP for clopidogrel). Transmission amplifies
when an agonist is added, platelets aggregate and light
transmission increases. Results are presented in percentage,
between 0 and 100, according to the degree of light transmis-
sion
14, 15. Also, the rate of aggregation is measured.Strana 354 VOJNOSANITETSKI PREGLED Volumen 69, Broj 4
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LTA test is still widely used, but there are many disad-
vantages of that method including sample preparation. Meth-
odology for preparation of PRP vary between different labo-
ratories including various types of anticoagulants used (cit-
rate or hirudin), different centrifugation speeds and times re-
ported. Some authors argue that whole blood tests of platelet
function are more reliable than PRP assays. In the latter case,
isolated platelets are analyzed, which is not their physiologi-
cal milieu. Also, PRP usually do not include all the platelets;
the most active and larger platelets may be lost during cen-
trifugation. In addition, other blood cells are present in the
whole blood – erythrocytes and leukocytes, which also inter-
fere with platelet aggregation. This technique is not stan-
dardized yet and different concentrations of ADP (5–20 μM)
are used. LTA test takes too long, it is laboratory-based,
blood samples should be sent as soon as possible to a labo-
ratory, and it requires trained technicians. Also, LTA assay is
not suitable to test on large number of samples, which is not
convenient for routine clinical practice (Table 1) 
15–17.
The VerifyNow System is a turbidimetric based optical
detection system, which measures platelet-induced aggrega-
tion. The VerifyNow P2Y12 assay is a whole blood, fast and
standardized point of care analyzer used to measure the level
of platelet P2Y12 receptor blockade. The system consists of
an instrument, a disposable assay device and quality control
materials. The assay device contains a lyophilized prepara-
tion of human fibrinogen-coated beads, platelet activators,
and buffer 
14. A patient`s sample is anticoagulated whole
blood, which is automatically dispensed from a blood col-
lection tube into an assay device by the instrument. The as-
say is based upon the ability of activated platelets to bind fi-
brinogen. Agglutination takes place once the activated
platelets are exposed to the fibrinogen coated micro particles
and in proportion to the number of the available platelet re-
ceptors. When platelets are activated, microbead aggregation
is more rapid and reproducible; therefore, platelet activation
is induced when the reagent ADP/prostaglandin E1
(ADP/PGE1) is incorporated into the assay channel. The
reagent is formulated to specifically measure P2Y12-
mediated platelet aggregation. Light transmittance increases
as activated platelets bind and aggregate fibrinogen-coated
beads. The instrument measures this change in optical signal
and expresses results in P2Y12 Reaction Units (PRU) and a
higher PRU reflects greater ADP mediated platelet reactivity.
ADP is used to activate platelets by binding to the P2Y12 and
P2Y1 receptors, while PGE1 is used to reduce the ADP-
induced P2Y1 activation which is contributed with increase
of the assay sensitivity. This assay is the most commonly
used method for monitoring of clopidogrel response in USA.
The Veritas study on 147 patients has shown that Veri-
fyNow P2Y12 Assay is a fast and sensitive test for monitor-
ing platelet inhibition during clopidogrel therapy 
18. The
main limitations of the test are well-known: it is a closed
system without the possibility of assay modification; car-
tridge can only be used for single analysis; delays in testing
or difficulties regarding specimen collection may produce
spurious results 
19.
Since clopidogrel irreversibly inhibits ADP binding to
the platelet P2Y
12 receptor and prevents subsequent phos-
phorilation of vasodilator-stimulated phosphoprotein
(VASP), the increase in VASP phosphorilation could be a
useful marker of clopidogrel resistance 
17. Standardized flow
cytometric VASP assay is used for determination the VASP
phosphorylation state of whole blood 
20. Flow citometry is a
powerful technique that simultaneously measures and then
analyzes multiple physical characteristics of single particles,
as they flow in a fluid stream through a beam of light. Pa-
rameters analyzed with such an assay include particle’s rela-
Table 1
Available methods for monitoring of clopidogrel response (modified from 
14–16)
Method Advantages Disadvantages
Light transmission aggre-
gometry
x Gold standard
x Predictive of outcomes
x Not standardized test (different reagents used, different
reagents concentration, different instruments)
x Sample preparation
x Platelet Rich Plasma test
x Time consuming (1h–3h)
VerifyNow P2Y12 Assay x Point of-care (POC) assay
x Whole blood test
x Simple, fast, small sample
volume
x Three test cartridges
x Widely used in USA
x Predictive of outcomes
x Rigidity
x Cartridge can only be used for single analysis
x Closed system
x One canal
Flow cytometry x Whole blood test
x Small blood volumes
x Preparation methods flexible
x Specialized laboratories
x Expensive instrument
x Complex for routine monitoring Experienced operator
Multiple electrode aggre-
gometry
x Point of-care (POC) assay
x Whole blood test
x Simple, fast, easy to learn
x Five channels for parallel tests
x Open system
x Predictive of outcomes
x Relative new method
x Lack of the corresponding number of studies
x Comparison with other methods uncertain
x No ready-made reagentsVolumen 69, Broj 4 VOJNOSANITETSKI PREGLED Strana 355
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tive size, relative granularity or internal complexity, and
relative fluorescence intensity. These characteristics are de-
termined using an optical-to-electronic coupling system that
records how the cell or particle scatters incident laser light
and emits fluorescence. The flow cytometric assay, like Ver-
ify Now System, uses combination of ADP and PGE
1 for
analysis of the clopidogrel response. Blood samples were
collected in 0.129 M sodium citrate vacutainer tubes and in-
cubated with PGE1 alone or PGE
1 and ADP, before fixation
with paraformaldehyde. After this procedure, platelets were
permeabilized with non–ionic detergent and labeled with a
monoclonal antibody 16C2, specifically directed against
serine 239 phosphorylated VASP, followed by a staining
reagent, polyclonal anti-mouse antibody IgG-FITC (fluores-
cein isothiocyanate). Platelet population was identified on its
forward and side scatter distribution and 10,000 platelet
events were gated. ADP receptor reactivity was calculated
using mean fluorescence intensities (MFI) in the presence of
PGE1 or PGE1+ADP according the corresponding formula.
There is an inverse correlation between clopidogrel treatment
efficacy and the ADP receptor reactivity ratio.
The main disadvantage of flow cytometry assay is that
it needs suspension of single cells or other particles, with
minimum clumps and debris. This means that tissue archi-
tecture and any information about the spatial relationship
among different cells are lost when single cells or nuclei are
prepared. Also, this test is too complex for routine monitor-
ing of clopidogrel and requires experienced person who will
perform analysis. Other limitations are total cost of the pro-
cedure, and interactions of drugs with VASP assay (e.g.
drugs affecting intracellular cyclic adenosine monophosphate
and/or nitric oxide (NO)/cyclic guanosine monophosphate
(cGMP) signals may influence VASP phosphorylation) 
21.
Multiple electrode aggregometry (MEA) is a new tech-
nique for detection of platelet function. This method is per-
formed to analyze platelet function in whole blood based on
impedance aggregometry. In Europe, the multiplate assay is
slowly but surely winning over other methods for monitoring
of clopidogrel resistance. The system registers the electrical
impedance change due to the aggregation of platelets on two
independent electrode set surfaces in the test cuvette and the
analysis are measured simultaneously on two sensor units-
internal QC. The obtained impedance is transformed to arbi-
trary aggregation units (AU) that are plotted against time
(AUmin) 
22. Like VerifyNow P2Y12 and flow cytometry as-
say, MEA uses ADP and PGE1 as agonists. Main advantages
of such a test involve the use of heparin and hirudin, because
these anticoagulants do not interfere with serum calcium, an
important second messenger of platelet activation and aggre-
gation. Also, MEA is rapid test; smaller samples of blood are
needed; up to five parallel samples could be analyzed at the
same time; electronic pipetting reduces operator errors and it
is easy to learn. However, MEA has not been sufficiently
tested in clinical settings as a relatively new method.
In general, there is a correlation between light transmis-
sion aggregometry ("gold standard") and other tests of
platelet function, e.g. VerifyNow P2Y12 assay, VASP assay
and MEA 
23–26. In addition, Varenhorst et al. 
27 reported that
the VerifyNowP2Y12 correlated strongly with inhibition of
P2Y12 receptors, as measured with either VASP or LTA. The
only exception is the Platelet Function Analyzer PFA-100, a
reliable test for monitoring of aspirin but not clopidogrel re-
sponse. Gremmel et al. 
28 investigated correlation between
LTA and other tests in the same time. These authors evalu-
ated clopidogrel response in 80 patients on combined anti-
platelet therapy after coronary stent implantation – throw
LTA, VerifyNowP2Y12, VASP assay, MEA and Impact R
measure of platelet inhibition. The results showed that all of
these methods correlated significantly with LTA, where
VerifyNowP2Y12 had the strongest correlation. Despite sig-
nificant correlation between LTA and VerifyNowP2Y12,
VASP assay, MEA and Impact R, registrated sensitivities
and specificities ranged from 55% to 35% and from 85% to
78.3%, respectively 
28. Unfortunately, it was not emphasized
in which patients this disagreement was detected. Similarly,
Paniccia et al. 
29 showed that MEA significantly correlated
with VerifyNowP2Y12 with moderate agreement and 81.5%
of concordant values. Also, a significant correlation was
shown between MEA and LTA with good agreement and
88.8% of concordant values.
When Bland-Altman analysis was used instead of cor-
relation, only a low agreement was found between light
transmission aggregometry, whole-blood aggregometry,
PFA-100 and VerifyNow P2Y12 Assay (randomized, double-
blind trial on 116 patients with stable coronary artery disease
treated with clopidogrel) 
30.
The importance of evaluating the (non)adequate re-
sponse to clopidogrel could be seen in a possible relation
with adverse cardiovascular events. Numerous studies have
found that low response to clopidogrel is associated with an
increased risk of ischemic events after percutaneous coro-
nary intervention (PCI) (Table 2) 
22, 31–34. In Excelsior study,
which investigated platelet function in 802 patients, throw
LTA, was shown that attenuated response to clopidogrel is
Table 2
Clinical implication of inadequate response to clopidogrel 
22, 31–34
Study Number of patients Method Results Outcome
Hochholzer et al, 2006 
31 802 LTA Ĺ Platelet aggregation 30-day MACE
Buonamici et al, 2007 
32 804 LTA Ĺ Platelet aggregation Stent thrombosis
Patti  et al, (ARMYDA PRO
Study)2008 
33 160 VerifyNow P2Y12
Ĺ PRU
(4
th quartile) 30-day MACE
Sibbing et al, 2009 
22 1608 MEA Ĺ Platelet reactivity Stent thrombosis
Siller-Matula et al, 2010 
34 416 MEA Ĺ Platelet reactivity Stent thrombosis
MACE – major adverse cardiac events; ARMYDA-PRO – Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty-Platelet
Reactivity Predicts Outcome; PRU – platelet (P2Y12) reaction units; LTA – light transmission aggregometry; MEA – multiple electrode aggregometryStrana 356 VOJNOSANITETSKI PREGLED Volumen 69, Broj 4
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an independent predictor of major adverse cardiac events
(MACE) 
31. Also, by using LTA assay, Buonamici et al. 
32
found that nonresponsiveness to clopidogrel is a strong and
independent predictor of stent thrombosis in patients re-
ceiving sirolimus- or paclitaxel-eluting stents. Other studies
using other methods have also reported on correlation re-
garding testing response to clopidogrel and cardiovascular
outcomes. In ARMYDA- PRO trial platelet reactivity was
evaluated in 160 patients before PCI and at 8 h and 24 h
after intervention with the VerifyNow P2Y12 assay. The
results have shown that pre-PCI PRU levels in the fourth
quartile were associated with 6-fold increase in risk of 30-
day MACE 
33. Sibbing et al. 
22 used MEA to detect the re-
sponse to clopidogrel. The authors found that a low re-
sponse to this thienopyridine is to a significant level asso-
ciated with higher risk of stent thrombosis. The predictive
value of MEA was also pointed on by Siller-Matula et al. 
34
who have examined platelet reactivity in their prospective
study with 416 patients by the use of MEA and VASP as-
say. These results have shown that MEA can predict stent
thrombosis better, than the VASP assay.
However, a prospective cohort study called Popular in-
volved 1,069 patients subjected to intracoronary stent im-
plantation and treated with clopidogrel. The primary end-
point (composite of all-cause death, nonfatal acute myocar-
dial infarction, stent thrombosis, and ischemic stroke) oc-
curred more frequently in patient with high on-treatment
platelet reactivity detected by the LTA, VerifyNow P2Y12,
and Plateletworks assay (11.7%, 13.3%, and 12.6%). Despite
a significant association between those tests and the primary
endpoint, their predictive accuracy was only modest 
35.
We found no significant difference in one-year mortality
between good and bed responders to clopidogrel in our open,
prospective, controlled study on 52 participants (VASP assay)
12. Also, myocardial infarction and/or revascularization did not
occur in good or bad responders during a follow-up period of
one year. However, an insufficient number of participants and
open design preclude firm conclusion from those data.
Finally, the role of a reduced platelet response to clopi-
dogrel in patients with certain comorbidities (e.g. type 2 dia-
betes) as compared with platelet function tests still remains
to be clarified 
36.
Conclusion
Thienopyridine (clopidogrel) resistance still remains to
be clarified. More well-designed clinical trials with a suffi-
cient number of participants are needed in order to draw
valid conclusions. The very first step in clopidogrel resis-
tance problem solving is to establish a unique platelet aggre-
gation test which is reliable, effective, simple and low cost.
Also, it would be useful to establish cut-off values for high
on-treatment platelet reactivity that provides accurate prog-
nostic information for high-risk patients subjected to intra-
coronary stent implantation.
The greatest benefit from the determination of response
to clopidogrel should have patients who need a long-term us-
age of this drug. Based on the response to clopidogrel is pos-
sible to decide on further course of treatment, in other words,
patients with inadequate response to the drug can receive ei-
ther a higher dose of clopidogrel or switch to another anti-
platelet drug.
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